New Gel Treatment for Diabetic Wounds Shows Promise

For those living with diabetes, elevated blood sugar levels can lead to serious damage to blood vessels and nerves, resulting in chronic wounds that can linger for months. However, a groundbreaking gel treatment may dramatically enhance the healing process, enabling wounds to close within just days, according to recent research.

This innovative treatment focuses on thrombospondin-1 (TSP-1), a protein known for impeding the formation of new blood vessels, which is essential for healing. By targeting TSP-1, researchers saw an increase in new blood vessel growth in human endothelial cells and diabetic mouse models, culminating in an impressive wound closure within two weeks. A collaboration of researchers from multiple institutions in China presented this technology in a study published in the journal Burns & Trauma.

“Our findings highlight the efficacy of merging advanced tissue engineering with molecular biology. By directing attention to TSP-1 through miR-221OE-sEVs contained in GelMA, we’ve not only boosted endothelial cell performance but also provided a local and lasting therapeutic impact,” stated Chuan’an Shen, a researcher from The Fourth Medical Center of Chinese PLA General Hospital.

Existing research indicates that diabetic wounds have elevated TSP-1 levels in endothelial cells—the cells that line blood vessels. This increased presence of TSP-1 obstructs their ability to replicate and function effectively. In response, the study’s researchers devised a method to lower TSP-1 levels.

The technology utilizes small extracellular vesicles (sEVs), which are tiny membrane-bound sacs released by cells, loaded with miR-221-3p, a microRNA that hinders TSP-1 production in endothelial cells.

These sEVs were encapsulated within a hydrogel that simulates the extracellular environment, allowing for a controlled and prolonged release of miR-221-3p directly at the wound site. In diabetic mouse models, this gel remarkably sped up healing, achieving a 90% wound closure rate within 12 days, in stark contrast to just 20% for untreated mice during the same timeframe.

The authors noted that the next step is to proceed with clinical trials for the new gel. “This advancement could potentially transform diabetes-related wound care, significantly enhancing the quality of life for patients,” Shen added.